Table 3. Treatment Interaction by Stent Type on Outcomes.
Analyses of treatment interaction by stent type, shown with Kaplan-Meier event rates, hazard ratios and 95% confidence intervals (CI) for efficacy and safety outcomes at 12-30 months among all randomized patients (9961 drug-eluting stent-treated and 1687 bare metal stent-treated).
| Continued Thienopyridine N (%) |
Placebo N (%) |
Hazard Ratio (95% CI) |
P Value for Interaction | |
|---|---|---|---|---|
|
| ||||
| No. of patients (%) | ||||
| Definite or Probable Stent Thrombosis* | 0.42 | |||
| DES | 19 (0.4) | 65 (1.4) | 0.29 (0.17,0.48) | |
| BMS | 4 (0.5) | 9 (1.1) | 0.49 (0.15,1.64) | |
| MACCE | 0.32 | |||
| DES | 211 (4.3) | 285 (5.9) | 0.71 (0.59,0.85) | |
| BMS | 33 (4.0) | 38 (4.7) | 0.92 (0.57,1.47) | |
| Death | 0.41 | |||
| DES | 98 (2.0) | 74 (1.5) | 1.36 (1.00,1.85) | |
| BMS | 8 (1.0) | 10 (1.2) | 0.90 (0.35,2.33) | |
| GUSTO Severe/Moderate Bleeding | 0.30 | |||
| DES | 119 (2.5) | 73 (1.5) | 1.60 (1.19,2.17) | |
| BMS | 16 (1.9) | 7 (0.9) | 2.74 (1.05,7.00) | |
| Myocardial Infarction | 0.04 | |||
| DES | 99 (2.1) | 198 (4.1) | 0.47 (0.37,0.61) | |
| BMS | 22 (2.7) | 25 (3.1) | 0.91 (0.51,1.62) | |
Abbreviations: BMS, bare metal stents; DES, drug-eluting stents; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Arteries; MACCE, major adverse cardiovascular and cerebrovascular events.
*
Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.